A Rational Pharmacotherapeutic Research Study on the Prescription Patterns of Anti-Tubercular Drugs Monotherapy or Combination Therapies in Multi Drug-Resistant Tuberculosis Patients at Tertiary Patientcare Hospitals
Authors/Creators
- 1. Associate Professor, Head of Department In Charge, Department of Pharmacology, Mamata Medical College and Hospitals, Telangana, India
Description
Background: This rational pharmacotherapeutic appraisal study was conducted to assess the maintenance of the various aspects of rational pharmacotherapeutics, including appropriateness, efficacy, safety, availability, and ease of administration in prescribing different anti-tubercular drugs, like ofloxacin, delamanid or bedaquiline, which reflected upon the prescription percentages of these drugs, thus delineating the choice of drugs, treatment regimens and the routine prescription patterns of anti-tubercular monotherapy or combination therapies, among multi-drug resistant tuberculosis patients, in multi-centre tertiary patientcare hospitals. Aim and Objectives: This rational pharmacotherapeutic research study was conducted to interprete the prescription patterns of anti-tubercular drugs monotherapy or combination therapies, among multi drug-resistant tuberculosis patients at tertiary patientcare hospitals. Materials and Methods: From the clinical prescriptions of 102 multi drug-resistant patients, thorough patients’ history with complete examination details and the prescription patterns were obtained with the study proforma, and the study data were observed, thoroughly analysed and recorded. For 24-48 weeks, these patients had been prescribed anti-tubercular drugs, like delamanid 100 mg twice daily, ofloxacin 400 mg twice daily, and bedaquiline 400 mg four times daily followed by 200 mg thrice weekly, as part of MDR-TB treatment regimens. The number of prescriptions for each drug were recorded, and the corresponding prescription rates were statistically derived in percentages. Results: The prescription frequency of delamanid was followed by ofloxacin and bedaquiline. Conclusion: Delamanid was more commonly prescribed anti-tubercular drug, followed by ofloxacin, which was less commonly prescribed, and finally followed by bedaquiline, which was the least prescribed anti-tubercular drug.
Abstract (English)
Background: This rational pharmacotherapeutic appraisal study was conducted to assess the maintenance of the various aspects of rational pharmacotherapeutics, including appropriateness, efficacy, safety, availability, and ease of administration in prescribing different anti-tubercular drugs, like ofloxacin, delamanid or bedaquiline, which reflected upon the prescription percentages of these drugs, thus delineating the choice of drugs, treatment regimens and the routine prescription patterns of anti-tubercular monotherapy or combination therapies, among multi-drug resistant tuberculosis patients, in multi-centre tertiary patientcare hospitals. Aim and Objectives: This rational pharmacotherapeutic research study was conducted to interprete the prescription patterns of anti-tubercular drugs monotherapy or combination therapies, among multi drug-resistant tuberculosis patients at tertiary patientcare hospitals. Materials and Methods: From the clinical prescriptions of 102 multi drug-resistant patients, thorough patients’ history with complete examination details and the prescription patterns were obtained with the study proforma, and the study data were observed, thoroughly analysed and recorded. For 24-48 weeks, these patients had been prescribed anti-tubercular drugs, like delamanid 100 mg twice daily, ofloxacin 400 mg twice daily, and bedaquiline 400 mg four times daily followed by 200 mg thrice weekly, as part of MDR-TB treatment regimens. The number of prescriptions for each drug were recorded, and the corresponding prescription rates were statistically derived in percentages. Results: The prescription frequency of delamanid was followed by ofloxacin and bedaquiline. Conclusion: Delamanid was more commonly prescribed anti-tubercular drug, followed by ofloxacin, which was less commonly prescribed, and finally followed by bedaquiline, which was the least prescribed anti-tubercular drug.
Files
IJTPR,Vol12,Issue3,Article7.pdf
Files
(874.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:def40a1cebbe54a25048005fb9f47c86
|
874.4 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-02-22
Software
References
- 1. Falzon D, Schunemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017; 49: 1602308. 2. D'Ambrosio L, Centis R, Sotgiu G, et al. New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Res. 2015; 1(1): 00010-2015. 3. Pontali E, Sotgiu G, Tiberi S, et al. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. Eur Respir J. 2018; 52: 1800934. 4. Sapkal PM, Pantwalawalkar JR. Tuberculosis Drug Resistance: An Overview. Int J Res Methodol. 2015; 1(2): 8-18. 5. Field SK. Safety and efficacy of delamanid in the treatment of multi-drug resistant tuberculosis (MDR-TB). Clin Med Insights Ther. 2013; 5: 137-149. 6. Chang KC, Yew WW. Management of difficult multi-drug resistant tuberculosis and extensively drug-resistant tuberculosis: Update 2012. Respirology. 2013; 18(1): 8-21. 7. Tiberi S, Scardigli A, Centis R, D'Ambrosio L, et al. Classifying new anti- tuberculosis drugs: rationale and future perspectives. Int J Infect Dis. 2017; 56: 181-184. 8. Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020; 92S: S15-S25. 9. Gupta R, Wells CD, Hittel N, et al. Delamanid in the treatment of multidrugresistant tuberculosis. Int J Tuberc Lung Dis. 2016; 20(12): S33-S37. 10. Santiago MR, Garfin AMC, Balanag VM. Introduction of bedaquiline for the treatment of drug-resistant TB in the Philippines. Int J Tuberc Lung Dis. 2020; 24(10): 1063-1066. 11. Hussain A, Singh S, Das SS, Anjireddy K, Karpagam S, Shakeel F. Nanomedicines as drug delivery carriers of anti-tubercular drugs: from pathogenesis to infection control. Curr Drug Deliv. 2019; 16(5): 400-429. 12. Nahid P, Mase SR, Miglior GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2020; 201: 500-501.